BioNTech (NASDAQ:BNTX) PT Raised to $132.00

BioNTech (NASDAQ:BNTX) had its price objective lifted by analysts at TD Cowen from $85.00 to $132.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. TD Cowen’s price objective suggests a potential upside of 19.05% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft raised their price target on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. JPMorgan Chase & Co. upgraded BioNTech from an “underweight” rating to a “neutral” rating and raised their price target for the company from $91.00 to $125.00 in a research note on Monday, September 16th. HSBC boosted their target price on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th. UBS Group boosted their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Finally, Bank of America upped their price objective on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.54.

BioNTech Stock Performance

BNTX stock opened at $110.88 on Monday. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $105.18 and its two-hundred day simple moving average is $94.37. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The firm has a market cap of $26.36 billion, a price-to-earnings ratio of 221.76 and a beta of 0.24.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business’s quarterly revenue was down 23.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.86) EPS. Analysts predict that BioNTech will post -3.04 earnings per share for the current year.

Institutional Investors Weigh In On BioNTech

Large investors have recently bought and sold shares of the company. Candriam S.C.A. lifted its stake in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares during the period. Point72 Asset Management L.P. raised its holdings in BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after purchasing an additional 341,311 shares during the period. SG Americas Securities LLC boosted its position in BioNTech by 610.5% during the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock worth $6,471,000 after purchasing an additional 60,270 shares in the last quarter. Acadian Asset Management LLC grew its holdings in BioNTech by 51.3% in the first quarter. Acadian Asset Management LLC now owns 111,398 shares of the company’s stock valued at $10,275,000 after purchasing an additional 37,792 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of BioNTech in the second quarter valued at approximately $2,892,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.